The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 5350 participants.

Also called NCT05836987

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 5,350 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05836987
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05836987. Randomized; single masking; primary purpose prevention. Start 2023-07-13 (actual); primary completion 2029-07-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
Acronym
REACT-AF
Intervention (Device)
AFSW Guided DOAC
Intervention (Drug)
Continuous DOAC therapy
Lead sponsor
Johns Hopkins University (class: other)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (class: US National Institutes of Health)
Collaborator
Northwestern University (class: other)

Record details

Record id
cardio:ct-nct05836987
Content hash
a21fd9f6fa247ac0a5bfbe9edb89b6556f8ddf6f2edf4118e144780144178c57